Year: 2021
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19. For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750), we searched MEDLINE, EMBASE, CINAHL and PsycINFO to 20 February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection and in control groups where available. For each study, a minimum of two authors extracted summary data. For each symptom, we calculated a pooled prevalence using generalized linear mixed models. Heterogeneity was measured with I2. Subgroup analyses were conducted for COVID-19 hospitalization, severity and duration of follow-up. From 2844 unique titles, we included 51 studies (n = 18 917 patients). The mean duration of follow-up after COVID-19 was 77 days (range 14–182 days). Study quality was most commonly moderate. The most prevalent neuropsychiatric symptom was sleep disturbance [pooled prevalence = 27.4% (95% confidence interval 21.4–34.4%)], followed by fatigue [24.4% (17.5–32.9%)], objective cognitive impairment [20.2% (10.3–35.7%)], anxiety [19.1% (13.3–26.8%)] and post-traumatic stress [15.7% (9.9–24.1%)]. Only two studies reported symptoms in control groups, both reporting higher frequencies in COVID-19 survivors versus controls. Between-study heterogeneity was high (I2 = 79.6–98.6%). There was little or no evidence of differential symptom prevalence based on hospitalization status, severity or follow-up duration. Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. The literature on longer-term consequences is still maturing but indicates a particularly high prevalence of insomnia, fatigue, cognitive impairment and anxiety disorders in the first 6 months after infection.
Source: Brain Communications
Authors: James B. Badenoch, Emma R. Rengasamy, Cameron Watson, Katrin Jansen, Stuti Chakraborty, Ritika D. Sundaram, Danish Hafeez, Ella Burchill, Aman Saini, Lucretia Thomas, Benjamin Cross, Camille K. Hunt, Isabella Conti, Sylvia Ralovska, Zain Hussain, Matthew Butler, Thomas A. Pollak, Ivan Koychev, Benedict D. Michael, Heinz Holling, Timothy R. Nicholson, Jonathan P. Rogers, Alasdair G. Rooney
Institutions: Queen Mary University of London, Barts Health NHS Trust, University of Cambridge, University of Münster, Christian Medical College, Vellore, University of Glasgow, Homerton University Hospital NHS Foundation Trust, King's College London, University College London, University of Birmingham, East Lancashire Hospitals NHS Trust, University of Warwick, Queen's University Belfast, Sofia University "St. Kliment Ohridski", University of Dundee, University of Edinburgh, University of Oxford, Oxford University Hospitals NHS Trust, University of Liverpool, Walton Centre, Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool, South London and Maudsley NHS Foundation Trust
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,400
Awards: UCL Wellcome Trust PhD Programme for Clinicians, Understanding cerebral inflammation in viral encephalitis - how does neuron-glial signalling drive blood-brain barrier permeability?, NIHR Development and Skills Enhancement Award, G4644249324, PsySTAR Programme (Psychiatry: Scottish Training in Academic Research Programme), G5516481097, G8338515980, The COVID-19 Clinical Neuroscience Study (COVID-CNS), UCL Wellcome Trust PhD Programme for Clinicians, G973851383
OpenAlex ID: W4205354784
